{"schema_version":"secwatch.filing_event.v1","accession":"0001013762-23-006323","form_type":"8-K","ticker":"ADIL","cik":"0001513525","company_name":"ADIAL PHARMACEUTICALS, INC.","filed_at":"2023-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.323880+00:00","generated_at":"2026-06-09T14:00:27.314994+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Adial raises $4M in private placement; issues warrants at $2.82","bullets":["Gross proceeds ~$4M from sale of 1.42M shares (or pre-funded warrants) and series A/B warrants.","Net proceeds ~$3.5M after fees; to fund AD04 clinical activities and working capital.","Warrants exercisable at $2.82/share after stockholder approval; Series A 5.5yr, Series B 18mo.","Company must file resale registration within 20 days, effective within 75 days.","60-day lock-up on new issuances; 1-year ban on variable rate transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001013762-23-006323","json":"https://secwatch.observer/filing/0001013762-23-006323.json","markdown":"https://secwatch.observer/filing/0001013762-23-006323.md","text":"https://secwatch.observer/filing/0001013762-23-006323.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1513525/000101376223006323/0001013762-23-006323-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1513525/000101376223006323/ea187091-8k_adialpharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T14:00:27.314994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e20da694d3b4fde68762566d784bb482f66b148c","claim":"ADIAL PHARMACEUTICALS, INC. entered into Purchase Agreement with an institutional investor valued at approximately $3.5 million (effective 2023-10-19).","evidence_excerpt":"On October 19, 2023, Adial Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Purchaser”) for the issuance and sale in a private placement (the “Private Placement”) of (i) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 1,418,440 shares of the Company’s common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1513525/000101376223006323/0001013762-23-006323-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an institutional investor"},{"label":"Value","value":"approximately $3.5 million"},{"label":"Effective","value":"2023-10-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}